Phase Ib and Phase II Studies of Anti-PD-1 Antibody MK-3475 in Combination With Bevacizumab for the Treatment of Metastatic Renal Cell Carcinoma: Big Ten Cancer Research Consortium GU14-003

Conditions

Kidney | Phase I

Phase I

Volunteers
Health Professionals

What is the purpose of this trial?

This is an open label, multi-institutional, single arm study of dose escalation phase Ib cohort, followed by a phase II cohort of anti-PD-1 antibody MK-3475 in combination with bevacizumab. No randomization or blinding is involved.

Find out more about who can participate in this trial

Trial with
Merck Sharp & Dohme LLC
Start Date
09/01/2022
End Date
12/05/2019

For more information about this study, contact:

Jimmy Nieves

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Harriet Kluger, MD
Harvey and Kate Cushing Professor of Medicine (Oncology) and of Dermatology; Director, Yale SPORE in Skin Cancer, Yale Cancer Center; Vice Chair for Translational Research, Internal Medicine; Chief, Division of Skin and Kidney Cancer; Associate Cancer Center Director, Education, Training and Faculty Development; Deputy Section Chief, Medical Oncology

Sub-Investigators

Last Updated
01/24/2023
Study HIC
#2000029978

Phase Ib and Phase II Studies of Anti-PD-1 Antibody MK-3475 in Combination With Bevacizumab for the Treatment of Metastatic Renal Cell Carcinoma: Big Ten Cancer Research Consortium GU14-003

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigators

Contact Information